Fiche publication
Date publication
mai 2026
Journal
Expert opinion on pharmacotherapy
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Bruno A, Bencardino S, D'Amico F, Peyrin-Biroulet L, Danese S
Lien Pubmed
Résumé
Acute severe ulcerative colitis is a potentially life-threatening manifestation of ulcerative colitis requiring hospitalization and prompt intervention. Despite corticosteroids being the cornerstone of initial therapy, 30-40% of patients exhibit steroid-refractory disease and require rescue treatment with infliximab or cyclosporine, with colectomy rates remaining substantial. The introduction of Janus kinase inhibitors, including tofacitinib, upadacitinib, and filgotinib, has expanded the therapeutic options for ulcerative colitis, offering a rapid onset of action and oral administration.
Mots clés
Acute severe ulcerative colitis, Janus Kinase inhibitors, filgotinib, tofacitinib, ulcerative colitis, upadacitinib
Référence
Expert Opin Pharmacother. 2026 05 20;:1-12
